Fu M L, Hoebeke J, Matsui S, Matoba M, Magnusson Y, Hedner T, Herlitz H, Hjalmarson A
Department of Clinical Pharmacology, Wallenberg Laboratory, Sahlgren's Hospital, University of Göteborg, Sweden.
Clin Immunol Immunopathol. 1994 Jul;72(1):15-20. doi: 10.1006/clin.1994.1101.
It was previously shown that the second extracellular loop of cardiovascular G-protein-coupled receptors is an antigenic target for pharmacologically active autoantibodies in patients with idiopathic dilated cardiomyopathy. To extend these observations to cover patients with the same disease from different geographical origins or to patients with other cardiac diseases, peptides corresponding to the sequences of the second extracellular loops of the human M2 muscarinic receptors and beta adrenoceptors were used as antigens in an enzyme immunoassay. Sera from patients from Sweden and Japan with idiopathic dilated cardiomyopathy (DCM, n = 32), hypertrophic cardiomyopathy (HCM, n = 23), malignant essential hypertension (MEH, n = 11), malignant secondary hypertension (MSH, n = 10), and sera from healthy blood donors (HBD, n = 49) were tested. Sera from patients with DCM recognized the muscarinic receptor peptide in 38% of cases and the beta 1 adrenoceptor peptide in 31% of cases. In 50% of the positive patients, autoantibodies against both peptides coexisted as shown by competition experiments using both peptides as inhibitors. In HCM patients, there was a lower frequency of autoantibodies but with a higher but not significant predominance against the M2 peptide. No autoantibodies were detected in sera from patients with MEH or MSH. Autoantibodies against the M2 muscarinic receptors, affinity-purified from positive patients, displayed pharmacological activity as demonstrated by changes in the affinity and number of radioligand binding sites. In contrast, antibodies purified from positive HBD had no effect. These results confirm that autoantibodies displaying pharmacological activity against G-protein-coupled cardiovascular receptors are mainly restricted to patients with idiopathic dilated cardiomyopathy and that different autoantibody populations are responsible for the recognition of the different receptors.
先前的研究表明,心血管G蛋白偶联受体的第二个细胞外环是特发性扩张型心肌病患者体内具有药理活性的自身抗体的抗原靶点。为了将这些观察结果扩展到来自不同地理区域的同一种疾病患者或其他心脏病患者,在酶免疫测定中,将与人M2毒蕈碱受体和β肾上腺素能受体第二个细胞外环序列相对应的肽用作抗原。检测了来自瑞典和日本的特发性扩张型心肌病(DCM,n = 32)、肥厚型心肌病(HCM,n = 23)、恶性原发性高血压(MEH,n = 11)、恶性继发性高血压(MSH,n = 10)患者的血清,以及健康献血者(HBD,n = 49)的血清。DCM患者的血清在38%的病例中识别出毒蕈碱受体肽,在31%的病例中识别出β1肾上腺素能受体肽。在50%的阳性患者中,使用两种肽作为抑制剂的竞争实验表明,针对两种肽的自身抗体共存。在HCM患者中,自身抗体的频率较低,但对M2肽的优势较高但不显著。在MEH或MSH患者的血清中未检测到自身抗体。从阳性患者中亲和纯化的针对M2毒蕈碱受体的自身抗体表现出药理活性,这通过放射性配体结合位点的亲和力和数量变化得以证明。相比之下,从阳性HBD中纯化的抗体没有作用。这些结果证实,对G蛋白偶联心血管受体具有药理活性的自身抗体主要局限于特发性扩张型心肌病患者,并且不同的自身抗体群体负责识别不同的受体。